Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones
LOS ALTOS, Calif., Jan. 23, 2024 (GLOBE NEWSWIRE) -- Unicycive Therapeutics, Inc. (Nasdaq: UNCY), a clinical-stage biotechnology company developing therapies for patients with kidney disease (the “Company or “Unicycive”), today issued a letter to shareholders.
- As I sit down to write this letter, I am filled with a profound sense of gratitude and excitement, energized for the year ahead.
- In this letter, I am pleased to recap for you another year of great accomplishments.
- We’ve made significant advancements in our clinical programs which will propel us to new heights in 2024.
- I would like to express my deep appreciation to the physician investigators, study participants, and especially to our dedicated Unicycive employees.